Clinical trials
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma clinical trials
Below are recruiting relapsed or refractory b-cell non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,759 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT06799026RecruitingPhase 1
Vaccine plus elranatamab for advanced multiple myeloma
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) mixed with myeloma cells, given together with a drug called elranatamab. It is for people with multiple myeloma that has not responded to at least three prior treatments.
Boston, MassachusettsAges 18 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21 - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07249905RecruitingPhase 1/Phase 2
Testing MDX2003 for people with relapsed B-cell lymphoma
This trial is testing a new drug, MDX2003, for people with certain types of lymphoma that have come back after at least two prior treatments. It aims to see how safe the drug is and if it can shrink tumors.
Richmond, VictoriaAges 18 years+ - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT07545603RecruitingPhase 2
XNW5004 tablets for hard-to-treat follicular lymphoma
This study tests a new tablet called XNW5004 in patients with follicular lymphoma (a type of blood cancer) that has come back or stopped responding after multiple prior treatments. The goal is to see if this drug can help control the cancer in patients who have limited options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06227026RecruitingPhase 1
CAR-T cell therapy for blood cancers that returned
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
Salt Lake City, UtahAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT06730256RecruitingEarly Phase 1
Cell therapy for hard-to-treat multiple myeloma and plasma cell leukemia
This study tests a new cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that is not responding to standard treatments or has come back. The therapy uses your own immune cells that are modified to fight the cancer.
Suzhou, JiangsuAges 18 years+ - NCT07769151Recruiting
BIO-FUNCTION to predict risks after stem cell transplant
This study looks at a new tool called BIO-FUNCTION to help predict the risk of serious complications or death after a stem cell transplant or cellular therapy. The goal is to better understand who might be at higher risk, so doctors can provide more personalized care.
Detroit, MichiganAges 18 years+ - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT07662018Recruiting
Study of stem cell transplant after chemo for children with germ cell tumors
This study looks at how well a stem cell transplant works after a specific combination of chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) in children and young adults up to age 21 whose germ cell tumors have come back or not responded to treatment. It may help doctors understand who benefits most from this approach.
Houston, TexasAges 21 years+ - NCT04047641RecruitingPhase 1/Phase 2
Quizartinib with chemotherapy for new or returning leukemia
This trial tests a combination of anti-leukemia drugs (including quizartinib) together with chemotherapy for people with acute myeloid leukemia (AML), a rare mixed-type leukemia, or high-risk myelodysplastic syndrome (MDS). It may help by trying to better control cancer in people whose disease is newly diagnosed or has returned/not responded to prior treatment.
Houston, TexasAges 18 years+ - NCT05445011RecruitingPhase 1
FLT3-targeted CAR-T for relapsed or resistant AML
This trial tests an engineered immune cell treatment (CAR-T) made to target FLT3, for adults with acute myeloid leukemia (AML) that has come back or did not respond to standard treatment. It aims to control the leukemia when options have been limited.
Wuhan, HubeiAges 18–70 - NCT06006117RecruitingPhase 3
Testing a new drug combination for relapsed marginal zone lymphoma
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
AnderlechtAges 18 years+ - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07078929RecruitingPhase 1
CAR T-cell therapy for children with relapsed or refractory ALL
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Bangkok, BangkoknoiAges 1–18
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell non-hodgkin lymphoma?
- Yes. Clin2 currently lists 1,759 recruiting relapsed or refractory b-cell non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.